MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
PRNewsWire
·
2026-04-23
·
via The Tech Buzz - Press Releases
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australi
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。